COMP <GO>
AXGN vs UNH // GROSS PROFIT MARGIN
Axogen Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: AXGN 4
— UNH 10
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $49.37 (-0.52%) • MKT CAP: $2.96B
gross-margins
74.30%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXGN VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXGN | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 74.30% | 88.57% | -14.27 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.60% | 11.47% | -14.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.10% | 6.48% | -6.58 | UNH | /fcf-yield <GO> |
| Operating Margin | -3.50% | 4.82% | -8.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -7.00% | 3.14% | -10.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 6.46% | +13.74 | AXGN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.64 | 3.12 | +15.52 | AXGN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.74% | +0.46 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 73.9 | 56.0 | +17.88 | AXGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.33 | +0.77 | AXGN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 17.1x | +0.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.96B | $364.66B | -$361.69B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXGN REV | UNH REV | AXGN GROSS % | UNH GROSS % | AXGN FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $225.2M | $447.57B | 74.3% | 88.7% | -$2.9M | $16.07B |
| FY 2024 | $187.3M | $400.28B | 75.8% | 88.3% | $1.4M | $20.70B |
| FY 2023 | $159.0M | $371.62B | 44.0% | 89.6% | -$12.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXGN // BETA 1.10
UNH // BETA 0.33